Table 2 Cardiovascular risk factors and treatment in early RA at baseline (T0) and after five years (T5)
Variables | T0 (n= 700) | T5 (n= 442) |
|---|---|---|
Hypertension, n (%) | 170 (24.5) | 164 (37.4)*** |
BP systolic, mmHg | 144.1 (22.6) | 141.2 (21.8)** |
BP diastolic, mmHg | 82.7 (10.3) | 81.0 (9.6)** |
Diabetes mellitus, n (%) | 48 (7.1) | 41 (9.5)** |
BMI | 26.3 (4.5) | 25.8 (4.3)* |
Smoking, present, n (%) | 196 (29.8) | 92 (22.4)*** |
Smoking, ever, n (%) | 451 (69.5) | - |
Previous CVE, n (%) | 72 (10.4) | - |
s-Cholesterol, mmol/L | 5.6 (1.1)1 | na |
s-HDL, mmol/L | 1.5 (0.5)1 | na |
s-Triglycerides, mmol/L | 1.5 (0.7)1 | na |
Statin treatment, n (%) | 54 (8.1) | 71 (16.4)*** |
NSAIDs, n (%) | 386 (58.5) | 357 (82.4)*** |
COX-2 inhibitors, n (%) | 82 (12.3) | 112 (25.7)*** |
Corticosteroids, ever, n (%) | 197 (29.1) | 367 (72.7)*** |
Corticosteroids, months (T0 to T5) | - | 22.3 (24.0) |
DMARDs ≤3 months after inclusion, n (%) | - | 393 (88.9) |
DMARDs, ever, n (%) | - | 429 (96.8) |
DMARDs months (T0 to T5) | - | 51 (16.4) |
Methotrexate ever, n (%) | - | 361 (81.5) |
Biologicals, ever, n (%) | - | 62 (14.2) |